CytRx,
a biopharm research and development company specializing in the development of
drug candidates for the field of oncology, was recently covered in an article
by Seeking Alpha contributor U.S. Biotech Investor, who reviews data from the
company’s recent phase 2b clinical trial data before issuing a bullish stance
on the company’s stock.
To
read the entire article visit
http://seekingalpha.com/instablog/15280302-u-s-biotech-investor/2523681-cytrx-corporations-aldoxorubicin-looks-like-a-winner
Aldoxorubicin
is an improved formulation of doxorubicin, a widely used but highly toxic
chemotherapy agent. CytRx recently released interim clinical data from a phase
2b trial in which aldoxorubicin demonstrated superiority to doxorubicin as
first-line treatment of soft tissue sarcomas (STS). Results showed that
patients administered aldoxorubicin were able to tolerate 3.5 times the
standard dose of doxorubicin with fewer side effects, resulting in greater
positive response to treatment.
“If
trials continue as successfully as they have, Investors should see
aldoxorubicin take the place of doxorubicin. CytRx Corporation will also find
an immediate market with a monstrous revenue stream,” writes U.S. Biotech
Investor.
The
article also recaps words from CytRx CEO Steven Kriegsman, who is quoted as
saying that aldoxorubicin’s underlying linker technology “has broad potential
utility with proven affinity to couple with multiple chemotherapeutic agents
including paclitaxel, docetaxel, cisplatin, irinotecan and methotrexate. Each
of these agents may be incorporated into our future clinical development
plans.”
A
brief summary of CytRx precedes the author’s conclusion that:
“CytRx
Corporation shares are in the start of a per share revaluation. The reset
forming is due to solid data released on a coming best in class cancer
treatment targeting soft-tissue sarcoma. The recent profit taking that occurred
after favorable data release spiked the share price has created an attractive
entry point. The savvy investor is now buying a position in Cytrx having had
the patience to wait out profit taking.”
For
more information visit www.cytrx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
